Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial

Aim. To evaluate the efficacy and safety of single bolus administration of non-immunogenic staphylokinase in comparison with placebo in patients with intermediatehigh risk pulmonary embolism (PE) within the FORPE-2 clinical trial.Material and methods. Non-immunogenic staphylokinase has high thrombol...

ver descrição completa

Detalhes bibliográficos

Principais autores:	S. N. Tereshchenko, E. B. Yarovaya, S. G. Leontiev, I. S. Yavelov, R. M. Shakhnovich, A. D. Erlikh, T. M. Uskach, D. V. Duplyakov, V. A. Kutsenko, O. E. Ivlev, A. G. Soplenkova, A. M. Semenov, M. P. Semenov, S. V. Ivanov, S. S. Markin
Formato:	Artigo
Idioma:	Russo
Publicado em:	«FIRMA «SILICEA» LLC 2025-03-01
coleção:	Российский кардиологический журнал
Assuntos:	intermediate-high risk pulmonary embolism thrombolysis non-immunogenic staphylokinase
Acesso em linha:	https://russjcardiol.elpub.ru/jour/article/view/6291
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!